GSK
GSK plcPrice & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Apretude sales growth | 44% | Q1 2026 call | — |
| Cabenuva sales growth | 31% | Q1 2026 call | — |
| General Medicines sales growth | -6% | Q1 2026 call | — |
| HIV sales growth | 10% | Q1 2026 call | — |
| HIV U.S. sales growth | 15% | Q1 2026 call | — |
| INSTI-led long-acting regimens share of HIV growth | 70% | Q1 2026 call | — |
| Jemperli sales | 232M | Q1 2026 call | — |
| Jemperli sales growth | 40% | Q1 2026 call | — |
| Nucala COPD market share | 45% | Q1 2026 call | — |
| Nucala total brand new patient starts growth | 65% | Q1 2026 call | — |
| Shingrix Europe sales growth | 51% | Q1 2026 call | — |
| Shingrix sales growth | 20% | Q1 2026 call | — |
| Shingrix U.S. sales growth | 12% | Q1 2026 call | — |
| Specialty Medicines sales growth | 14% | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GSK
this stock
GSK plc
|
$106.79B | +10.6% | — | — | 0.4% |
|
LLY
ELI LILLY & Co
|
$1.13T | +11.9% | +44.7% | 42.6 | 1.0% |
|
JNJ
Johnson & Johnson
|
$624.26B | +26.0% | +6.0% | 30.1 | 1.1% |
|
ABBV
AbbVie Inc.
|
$453.68B | +12.4% | +8.6% | 126.5 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$318.26B | +24.2% | +1.4% | 36.3 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GSK | +1.0% | +3.5% | +7.6% | +1.7% | +10.6% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -2.1% | +4.3% | -0.6% | +1.1% | +0.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.